Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.69 |
| ▸ | NPC1 | O15118 | 8/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | CASP2 | P42575 | 1/20 | 0.65 |
| ▸ | SCD | O00767 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9988448 | 0.88 | MAPT (0.72) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2791137 | 0.88 | NPC1 (0.65) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| Potassium Ion SCHEMBL2790234 | 0.88 | ABL1 (0.66) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1282877 | 0.88 | ABL1 (0.83) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2792432 | 0.86 | ABL1 (0.64) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2759558 | 0.86 | RAB9A (0.71) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2732073 | 0.85 | RAB9A (0.66) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2793209 | 0.84 | DYRK1A (0.65) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL213883 | 0.82 | GSK3B (0.78) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| Frentizole SCHEMBL599582 | 0.82 | RAB9A (1.00) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10231954-B2 | Neurodegenerative therapies | LYTIX BIOPHARMA AS (NO) | 2019-03-19 | — | — | US | disclosed |
| US-20170007583-A1 | Neurodegenerative Therapies | PHARMASUM THERAPEUTICS AS (NO) | 2017-01-12 | — | — | US | disclosed |
| EP-3102202-A1 | NEURODEGENERATIVE THERAPIES | Lytix Biopharma AS (NO) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015118026-A1 | NEURODEGENERATIVE THERAPIES | LYTIX BIOPHARMA AS (NO) | 2015-08-13 | — | — | WO | disclosed |
| US-9012481-B2 | Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-21 | — | — | US | disclosed |
| US-9012481-B2 | Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-21 | — | — | US | disclosed |
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-12-29 | — | — | US | disclosed |
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-12-29 | — | — | US | disclosed |
| WO-2010077068-A2 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10231954-B2 | Neurodegenerative therapies | OXSR1, MAPT, TTBK1 | RAB9A 2725/4885NPC1 425/4885KMT2A 3790/4885 |
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | HTT, PSEN1, PYGB | RAB9A 3642/4885NPC1 42/4885KMT2A 3011/4885 |
| US-20170007583-A1 | Neurodegenerative Therapies | OXSR1, MAPT, TTBK1 | RAB9A 2737/4885NPC1 430/4885KMT2A 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.